SIETES :: 92806 citas

Resultados de la búsqueda por FUROSEMIDA REFINAR BÚSQUEDA

1.

Moore N, Duret S, Grolleau A, Lassalle R, Barbet V, Duong M, Thurin N, Droz-Perroteau C, Gulmez SE. Previous drug exposure in patients hospitalised for acute liver injury: a case-population study in the French National Healthcare Data System. Drug Saf 2019;42:abril. [Ref.ID 103083]

2.

Anónimo. Sulfonamide cross-reactivity. The Medical Letter on Drug and Therapeutics Bulletin 2019;61:25 de marzo. [Ref.ID 103061]

3.

Vozoris NT, Wang X, Austin PC, O'Donnell DE, Aaron SD, To TM, Gershon AS. Incident diuretic drug use and adverse respiratory events among older adults with chronic obstructive pulmonary disease . Br J Clin Pharmacol 2018;84:marzo. [Ref.ID 102651]

4.

Montané E, Arellano AL, Sanz Y, Roca J, Farré M. Drug-related deaths in hospital inpatients: a retrospective cohort study. Br J Clin Pharmacol 2017;84:1. [Ref.ID 102184]

5.

Ruggiero A, Ferrara P, Attinà G, Rizzo D, Riccardi C. Renal toxicity and chemotherapy in children with cancer. Br J Clin Pharmacol 2017;83:2605-14. [Ref.ID 102170]

6.

Laatikainen O, Mietttunen J, Sneck S, Lehtiniemi H, Tenhunen O, Turpeinen M. The prevalence of medication-related adverse events in inpatients-a systematic review and meta-analysis. Eur J Clin Pharmacol 2017;73:1539-49. [Ref.ID 102145]

7.

Alharbi FF, Souverein PC, de Groot MCH, Blom MT, de Boer A, Klungel OH, Tan HL. The impact of serum potassium-influencing antihypertensive drugs on the risk of out-of-hospital cardiac arrest: a case–control study. Br J Clin Pharmacol 2017;83:2541-8. [Ref.ID 102115]

8.

Greenway T, Ross JS. US drug marketing: how does promotion correspond with health value?. BMJ 2017;357:j1855. [Ref.ID 101571]

9.

Anónimo. Lévosimendan et décompensation d'une insuffisance cardiaque. Prescrire 2017;37:245-7. [Ref.ID 101528]

10.

Solomon DH, Liu C-C, Kuo I-H, Zak A, Kim SC. Effects of colchicine on risk of cardiovascular events and mortality among patients with gout: a cohort study using electronic medical records linked with Medicare claims . Ann Rheum Dis 2016;75:1674-9. [Ref.ID 100659]

11.

Munson JC, Bynum JPW, Bell J-E, Cantu R, McDonough C, Wang Q, Tosteson TD, Tosteson ANA. Patterns of prescription drug use before and after fragility fracture. JAMA Intern Med 2016;176:1531-8. [Ref.ID 100584]

12.

Finch A, Kubler P. The management of gout. Australian Prescriber 2016;39:1 de agosto. [Ref.ID 100572]

13.

Zhang F, Mamtani R, Scott FI, Goldberg DS, Haynes K, Lewis JD. Increasing use of prescription drugs in the United Kingdom. Pharmacoepidemiol Drug Saf 2016;25:628-36. [Ref.ID 100019]

14.

Anónimo. Hyponatrémies d'origine médicamenteuse. Prescrire 2015;35:666-71. [Ref.ID 99717]

15.

Anónimo. Pertes d'auditions d'origine médicamenteuse. Prescrire 2014;34:428-35. [Ref.ID 97948]

16.

Myat A, Redwood SR, Qureshi AC, Spertus JA, Williams B. Resistant hypertension. BMJ 2012;345:40-5. [Ref.ID 94142]

17.

DeMarco MAM, Maynard JW, Baer AN, Gelber AC, Young JH, Alonso A, Coresh J. Diuretic use, increased serum urate levels, and risk of incident gout in a population-based study of adults with hypertension: The Atherosclerosis Risk in Communities cohort study. Arthritis & Rheumatism 2012;64:121. [Ref.ID 92602]

18.

Franz CC, Egger S, Born C, Bravo AER, Krähenbühl S. Potential drug-drug interactions and adverse drug reactions in patients with liver cirrhosis. Eur J Clin Pharmacol 2012;68:179-88. [Ref.ID 92329]

19.

Anónimo. Troubles de la vision des couleurs d'origine médicamenteuse. Prescrire 2012;32:113-6. [Ref.ID 92321]

20.

Garrison SR, Dormuth CR, Morrow RL, Carney GA, Khan KM. Nocturnal leg cramps and prescription use that precedes them: a sequence symmetry analysis. Arch Intern Med 2012;172:120-6. [Ref.ID 92270]